February 24, 2017

New Book Offers Fresh Take on Neurodegenerative Diseases by Focusing on Shared Features

Aim is to find new insights among unifying principles

17-NEU-551-Cummings-589583890-650×450

When it comes to age-related neurodegenerative diseases, similarities matter. That’s the premise behind a distinctive new academic text edited by two Cleveland Clinic brain health experts.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Neurodegenerative Diseases: Unifying Principles was released in late 2016 by Oxford University Press. Co-editors Jeffrey Cummings, MD, ScD, and Jagan Pillai, MD, PhD, both of Cleveland Clinic Lou Ruvo Center for Brain Health, say they developed the book explicitly to explore the shared features and challenges linking conditions such as Alzheimer’s, Parkinson’s and Huntington’s diseases.

17-NEU-551_Inset

“Our field increasingly recognizes the common biological and pathological features across seemingly varied neurodegenerative disorders that involve protein misfolding dysfunction and its long-term consequences,” explains Dr. Pillai.

“Conventional approaches emphasize the differences among neurodegenerative diseases,” adds Dr. Cummings, Director of the Lou Ruvo Center for Brain Health. “This book is the result of a conceptual revolution over the past decade or so in our understanding of these diseases as sharing many unifying features. Providing an overview of this conceptual change is a key theme of the book.”

Advertisement

The co-editors set out to do so by assembling a roster of international expert authors to provide insights on their subspecialty areas across the 360-page book’s 19 interrelated chapters.

Most chapters aim to identify common threads among neurodegenerative disorders, be they in molecular biology, pathology, neuroinflammation, physiology, genetics and epigenetics, biomarkers, behavioral syndromes, treatment strategies and more.

“The specific aim is to present a thorough examination of unifying principles from the subcellular to the systems and clinical levels,” notes Dr. Pillai. “The broader goal is to enable better patient care and promote research collaboration across multiple subspecialties to help advance insights and facilitate novel therapies.”

Such cross-fertilization of ideas is a definite goal, Dr. Cummings emphasizes: “Given the compelling evidence that neurodegenerative diseases share many features, insights in one may be rapidly translated into advances in another.”

Advertisement

For more on the book, visit the Oxford University Press site.

Related Articles

23-NEU-3516858-brain-trauma-650×450
January 30, 2023
Neurotrauma Guidelines: Where They’ve Been, Where They’re Headed and How to Make the Most of Them

Q&A with Brain Trauma Foundation guideline architect Gregory Hawryluk, MD, PhD

20-NEU-2020111 neuroimmunology_650x450
December 30, 2020
Autoimmune Neurologic Disorders: Treatable Conditions That Should Not Be Missed

Q&A with newly arrived autoimmune neurology specialist Amy Kunchok, MD

20-NEU-1984276 multimodal-monitoring_650x450
October 6, 2020
Multimodal Monitoring in the Neuro ICU: Essentials for Clinicians (Podcast)

A neurocritical care specialist shares what’s spurring growth of this new evaluation approach

20-NEU-1931313-Parkinsons-brain-650×450
September 2, 2020
More Patients Can Benefit From Functional Interventions for Parkinson’s, Essential Tremor (Podcast)

Focused ultrasound offers a newer alternative to deep brain stimulation

frailty
August 18, 2020
The Importance of Screening for Frailty in Patients with Spinal Conditions (Podcast)

Prehabilitation can help improve outcomes after spine surgery

central vein sign in multiple sclerosis
August 4, 2020
New Frontiers in Diagnosing and Monitoring Multiple Sclerosis (Podcast)

Get ready for central vein sign and optical coherence tomography

20-NEU-1938374-migraine_650x450
August 3, 2020
CGRP Antagonists for Decreasing Migraine Frequency: A Primer

How these new drugs fit into practice two years out from their first approvals

20-NEU-1892171 CQD_650x450_CCC-1901608_06-03-20_0443
July 2, 2020
What’s Afoot and What’s Ahead for Physical Medicine and Rehabilitation

A conversation on the state of physiatry with the AAPM&R’s Vice President

Ad